Back

Polypharmacy

Substack
polypharmacy.substack.com· weekly· Published 10 days ago

A psychiatrist's Substack examining the evidence base and marketing practices around transcranial magnetic stimulation for depression, including the claim that TMS trial data are weaker than commonly presented. It also covers the speed of antipsychotic action and the pharmacology behind it, drawing on the clinical literature.

tmstranscranial magnetic stimulationdepression treatmentantipsychoticspsychiatric marketingmeta-analysisclinical trialsolanzapinertmspsychiatry evidenceantidepressants
Platform
Substack
Frequency
Weekly
Latest issue
Oct 20, 2026
Language
English
Written for
Psychiatrists, clinicians, and informed readers interested in psychiatric research
Tone
analytical
Tracked since
Oct 29, 2026

Website: https://polypharmacy.substack.com